Last reviewed · How we verify
Basiliximab, Tacrolimus, MMF
This triple immunosuppressive regimen suppresses T-cell activation and proliferation to prevent organ rejection after transplantation.
This triple immunosuppressive regimen suppresses T-cell activation and proliferation to prevent organ rejection after transplantation. Used for Prevention of acute organ rejection in solid organ transplant recipients.
At a glance
| Generic name | Basiliximab, Tacrolimus, MMF |
|---|---|
| Also known as | Simulect, Advagraf, CellCept |
| Sponsor | University Hospital Freiburg |
| Drug class | Immunosuppressive combination therapy |
| Target | IL-2 receptor (basiliximab); calcineurin (tacrolimus); IMPDH (MMF) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Transplantation |
| Phase | FDA-approved |
Mechanism of action
Basiliximab is a chimeric monoclonal antibody that blocks the IL-2 receptor on T cells, preventing their activation. Tacrolimus is a calcineurin inhibitor that suppresses T-cell cytokine production. Mycophenolate mofetil (MMF) inhibits inosine monophosphate dehydrogenase, selectively suppressing lymphocyte proliferation. Together, these agents provide multi-target immunosuppression to prevent allograft rejection.
Approved indications
- Prevention of acute organ rejection in solid organ transplant recipients
Common side effects
- Infection (bacterial, viral, fungal)
- Nephrotoxicity
- Hypertension
- Hyperglycemia
- Tremor
- Gastrointestinal disturbances
- Neurotoxicity
Key clinical trials
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
- Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients (PHASE4)
- Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant (PHASE4)
- Simulect Versus ATG in Sensitized Renal Transplant Patient (PHASE4)
- A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients (PHASE2)
- Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR (PHASE4)
- Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major (PHASE4)
- Mesenchymal Stromal Cells in Living Donor Kidney Transplantation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Basiliximab, Tacrolimus, MMF CI brief — competitive landscape report
- Basiliximab, Tacrolimus, MMF updates RSS · CI watch RSS
- University Hospital Freiburg portfolio CI